Masoud Afshar, MD
Nephrology · Imperial, CANPI 1225287378
Payments from drug & device makers
Across 311 payments — averaging $28.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Amgen$1K
- Bayer$885
- Aurinia Pharma U.S., Inc.$619
- Mallinckrodt Hospital Products Inc.$573
- Calliditas Therapeutics US Inc.$430
- plus $3K from 26 others
What the payments were for
- Speaking & faculty fees$4005%
- Food & beverage$8,26295%
- Education$741%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 34 | $1,758 |
| Amgen(2 entities) | 43 | $1,185 |
| Bayer | 41 | $885 |
| Aurinia Pharma U.S., Inc. | 19 | $619 |
| Mallinckrodt Hospital Products Inc. | 15 | $573 |
| Calliditas Therapeutics US Inc. | 15 | $430 |
| Ardelyx, Inc. | 15 | $402 |
| Gastroklenz, Inc. DBA Cloudcath | 1 | $400 |
| Vifor Pharma, Inc. | 18 | $326 |
| OPKO Pharmaceuticals, LLC | 13 | $235 |
| GSK | 7 | $223 |
| Otsuka America Pharmaceutical, Inc. | 10 | $213 |
| Boehringer Ingelheim | 9 | $209 |
| Fresenius USA Marketing, Inc. | 11 | $179 |
| Boston Scientific | 2 | $160 |
| Novo Nordisk | 6 | $115 |
| Lilly USA, LLC | 6 | $105 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| ANI Pharmaceuticals, Inc. | 4 | $90 |
| Travere Therapeutics, Inc. | 20 | $79 |
| Novartis | 3 | $67 |
| Alnylam Pharmaceuticals Inc. | 3 | $58 |
| Akebia Therapeutics Inc | 3 | $53 |
| Mallinckrodt Enterprises LLC | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $42 |
| Shield Therapeutics Inc | 1 | $41 |
| Bard Peripheral Vascular, Inc. | 1 | $32 |
| Daiichi Sankyo Inc. | 2 | $29 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| AbbVie | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,736 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 83 | $290,749 |
| KerendiaFinerenone | 228 | $155,629 |
| FarxigaDapagliflozin Propanediol | 177 | $136,696 |
| LokelmaSodium Zirconium Cyclosilicate | 178 | $135,989 |
| TradjentaLinagliptin | 184 | $107,263 |
| XphozahTenapanor Hcl | 35 | $99,707 |
| VeltassaPatiromer Calcium Sorbitex | 89 | $99,184 |
| ProcritEpoetin Alfa | 118 | $78,966 |
| OzempicSemaglutide | 67 | $61,793 |
| Sevelamer Carbonate | 230 | $44,165 |
| JardianceEmpagliflozin | 39 | $34,223 |
| AuryxiaFerric Citrate | 17 | $30,032 |
| LinzessLinaclotide | 34 | $28,075 |
| EliquisApixaban | 32 | $20,621 |
| RybelsusSemaglutide | 11 | $20,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $179 | $290,74983 claims |
| AstraZenecaFarxiga, Lokelma | $1,758 | $272,686355 claims |
| BayerKerendia | $885 | $155,629228 claims |
| Boehringer IngelheimTradjenta, Jardiance | $209 | $141,486223 claims |
| Novo NordiskOzempic, Rybelsus | $115 | $82,21478 claims |
| Akebia Therapeutics IncAuryxia | $53 | $30,03217 claims |
| AbbVieLinzess | $21 | $28,07534 claims |
| NovartisEntresto | $67 | $14,93518 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $24 | $14,70728 claims |
| Lilly USA, LLCTrulicity | $105 | $14,25614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.
Other nephrology in Imperial
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.